<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(4)</volume><submitter>Asano Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The neutrophil/lymphocyte ratio (NLR) has been reportedly associated with prognosis in cancer patients by influencing both cancer progression and chemosensitivity. However, the correlation between NLR and the outcome of neoadjuvant chemotherapy (NAC) in breast cancer patients remains unclear.&lt;h4>Methods&lt;/h4>NLR was evaluated in 177 patients with breast cancer treated with NAC with 5-fluorouracil, epirubicin, and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery. The correlation between NLR and prognosis, including the efficacy of NAC, was evaluated retrospectively.&lt;h4>Results&lt;/h4>NLR ranged from 0.5 to 10.6. Fifty-eight patients with low NLR (&lt;3.0) had a higher pathological complete response (pCR) rate (p &lt; 0.001) and were more frequently di</pubmed_abstract><journal>Annals of surgical oncology</journal><pagination>1104-10</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4773470</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.</pubmed_title><pmcid>PMC4773470</pmcid><pubmed_authors>Takashima T</pubmed_authors><pubmed_authors>Noda S</pubmed_authors><pubmed_authors>Asano Y</pubmed_authors><pubmed_authors>Onoda N</pubmed_authors><pubmed_authors>Kawajiri H</pubmed_authors><pubmed_authors>Hirakawa K</pubmed_authors><pubmed_authors>Ohsawa M</pubmed_authors><pubmed_authors>Kitagawa S</pubmed_authors><pubmed_authors>Kashiwagi S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.</name><description>&lt;h4>Background&lt;/h4>The neutrophil/lymphocyte ratio (NLR) has been reportedly associated with prognosis in cancer patients by influencing both cancer progression and chemosensitivity. However, the correlation between NLR and the outcome of neoadjuvant chemotherapy (NAC) in breast cancer patients remains unclear.&lt;h4>Methods&lt;/h4>NLR was evaluated in 177 patients with breast cancer treated with NAC with 5-fluorouracil, epirubicin, and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery. The correlation between NLR and prognosis, including the efficacy of NAC, was evaluated retrospectively.&lt;h4>Results&lt;/h4>NLR ranged from 0.5 to 10.6. Fifty-eight patients with low NLR (&lt;3.0) had a higher pathological complete response (pCR) rate (p &lt; 0.001) and were more frequently di</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Apr</publication><modification>2025-04-18T22:02:27.503Z</modification><creation>2019-03-27T02:10:15Z</creation></dates><accession>S-EPMC4773470</accession><cross_references><pubmed>26511266</pubmed><doi>10.1245/s10434-015-4934-0</doi></cross_references></HashMap>